Gracell Biotechnologies Alpha and Beta Analysis
| GRCLDelisted Stock | USD 4.02 0.26 6.07% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Gracell Biotechnologies. It also helps investors analyze the systematic and unsystematic risks associated with investing in Gracell Biotechnologies over a specified time horizon. Remember, high Gracell Biotechnologies' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Gracell Biotechnologies' market risk premium analysis include:
Beta 1.4 | Alpha 1.25 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Gracell |
Gracell Biotechnologies Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Gracell Biotechnologies market risk premium is the additional return an investor will receive from holding Gracell Biotechnologies long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Gracell Biotechnologies. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Gracell Biotechnologies' performance over market.| α | 1.25 | β | 1.40 |
Gracell Biotechnologies Fundamentals Vs Peers
Comparing Gracell Biotechnologies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Gracell Biotechnologies' direct or indirect competition across all of the common fundamentals between Gracell Biotechnologies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Gracell Biotechnologies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Gracell Biotechnologies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Gracell Biotechnologies to competition |
| Fundamentals | Gracell Biotechnologies | Peer Average |
| Return On Equity | -0.32 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Current Valuation | 3.32 B | 16.62 B |
| Shares Outstanding | 96.57 M | 571.82 M |
| Shares Owned By Insiders | 16.39 % | 10.09 % |
| Shares Owned By Institutions | 63.11 % | 39.21 % |
| Number Of Shares Shorted | 1.19 M | 4.71 M |
Gracell Biotechnologies Opportunities
Gracell Biotechnologies Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Gracell Biotechnologies Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Gracell or other delisted stocks. Alpha measures the amount that position in Gracell Biotechnologies has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Gracell Biotechnologies Upcoming Company Events
As portrayed in its financial statements, the presentation of Gracell Biotechnologies' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gracell Biotechnologies' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Gracell Biotechnologies' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Gracell Biotechnologies. Please utilize our Beneish M Score to check the likelihood of Gracell Biotechnologies' management manipulating its earnings.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Gracell Biotechnologies
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |